Used in the treatment of rheumatoid arthritis, this antibody targets cadherin-11 to inhibit fibroblast-like synoviocyte activity, reducing joint inflammation and structural damage. It modulates cell-cell adhesion in synovial tissue, helping to suppress the progression of autoimmune joint destruction. Investigated in clinical trials for its potential in other fibrotic and inflammatory conditions involving abnormal cadherin-11 expression.